Tilray Brands, Inc 8-K/A, filed Mar 4, 2020
Tilray Brands, Inc. (TLRY)
About this 8-K/A
Tilray Brands, Inc filed this 8-K/A on March 4, 2020, reporting on events of March 2, 2020.
Items reported
- Item 2.02: Financial results
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
| Item 2.02 | Results of Operations and Financial Condition. |
This Form 8-K/A corrects the average cannabis net selling price per gram in Exhibit 99.1 of the Original Form 8-K, in the manner set forth immediately following this paragraph. No other changes are made to the Original Form 8-K by this Form 8-K/A.
Average cannabis net selling price per gram decreased to $3.01 (C$3.90) compared to $6.63 (C$8.63) in the prior year period.
Average cannabis net selling price per gram decreased to $1.87 (C$2.43) compared to $7.52 (C$10.05) in the prior year. The average net selling price excluding excise taxes for adult-use was $3.19 (C$4.16) per gram for the fourth quarter of 2019. The decrease was due to a shift in product and channel mix.
The information in this Item 2.02 of this current report on Form 8-K and the press release attached as Exhibit 99.1 hereto, is being furnished, but shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
| Item 8.01 | Other Events. |
This Form 8-K/A corrects average cannabis net selling price per gram in Item 7, Management Discussion and Analysis of Financial Condition and Results of Operations, of the Form 10-K, in the manner set forth immediately following this paragraph. No other changes are made to the Form 10-K by this Form 8-K/A.
| Year Ended December 31, |
2019 vs 2018 |
2018 vs 2017 |
||||||||||||||||||||||||||
| 2019 |
2018 |
2017 |
Qty/$ |
% |
Qty/$ |
% |
||||||||||||||||||||||
| Kilogram equivalents sold- cannabis |
35,380 |
6,478 |
3,024 |
28,902 |
446 |
% | 3,454 |
114 |
% | |||||||||||||||||||
| Kilograms harvested - cannabis |
50,144 |
11,022 |
6,779 |
39,122 |
355 |
% | 4,243 |
63 |
% | |||||||||||||||||||
| Thousand units sold - hemp products |
7,826 |
— |
— |
N/A |
N/A |
N/A |
N/A |
|||||||||||||||||||||
| Average net selling price per gram - cannabis |
$ | 3.01 |
$ | 6.63 |
$ | 6.52 |
$ | (3.62 |
) | (55 |
)% | $ | 0.11 |
2 |
% | |||||||||||||
| Average cost per gram sold - cannabis |
$ | 2.36 |
$ | 3.73 |
$ | 2.84 |
$ | (1.37 |
) | (37 |
)% | $ | 0.89 |
31 |
% | |||||||||||||
| Average gross selling price per unit -hemp products |
$ | 7.65 |
— |
— |
N/A |
N/A |
N/A |
N/A |
||||||||||||||||||||
The average net selling price per gram decreased during 2019 compared to 2018 due to a shift in distribution channels and product mix. Since legalization, adult use products increased to 51% of total revenue. Adult-use products are sold directly to wholesalers, which have lower sales price per gram and higher sales volume compared to medical channel sales.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |||
| 99.1 |
||||
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Tilray, Inc. | ||||||
| Date: March 3, 2020 |
By: |
/s/ Brendan Kennedy | ||||
| Brendan Kennedy | ||||||
| President and Chief Executive Officer | ||||||
Exhibit 99.1
| PRESS RELEASE |
March 2, 2020 |
Tilray, Inc. Reports Fourth Quarter and Full Fiscal Year 2019 Financial Results
Revenue Increased 287% to $167.0 (C$217.4) Million in Full Fiscal Year 2019 Compared to the Prior Year
Adult-Use Revenue Increased Over Three-Fold in the Fourth Quarter Compared to the Prior Year Period; 7% Sequential Quarterly Revenue Growth
Signed and Closed $60 Million Senior Credit Facility
NANAIMO, BRITISH COLUMBIA – Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, reports financial results for the fourth quarter and full fiscal year ended December 31, 2019. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“Our full year results demonstrate strong sales growth momentum, which we expect to continue in 2020,” said Brendan Kennedy, Tilray’s Chief Executive Officer. “Like our peers, we have faced industry challenges, but we remain committed to driving long-term value for our shareholders. Tilray has a diversified business model comprised of global medical, Canada adult-use and hemp products which positions us well in the current volatile market environment. We are still in the early days of this emerging growth industry and will continue being good stewards of shareholder capital as we aim to build the world’s most trusted and valued cannabis and hemp company.”
2019 Financial Highlights
| ● | Revenue increased to $167.0 (C$217.4) million, up 287.2% compared to last year. The increase in revenue was driven by significant growth in sales for the Canadian adult-use market, international medical markets as well as the acquisition of Manitoba Harvest. |
| For the three months ended December 31, | For the year ended December 31, | |||||||||||||||||||||||||||||||
| 2019 | 2018 | $ Change | % Change | 2019 | 2018 | $ Change | % Change | |||||||||||||||||||||||||
| Cannabis |
||||||||||||||||||||||||||||||||
| Adult-use |
$ | 17,007 | $ | 4,660 | $ | 12,347 | 265% | $ | 55,763 | $ | 3,521 | $ | 52,242 | N/A | ||||||||||||||||||
| Canada - medical |
3,332 | 2,845 | 487 | 17% | 12,556 | 18,052 | (5,496) | (30)% | ||||||||||||||||||||||||
| International - medical |
4,008 | 1,056 | 2,952 | 280% | 13,378 | 2,912 | 10,466 | 359% | ||||||||||||||||||||||||
| Bulk |
3,924 | 6,970 | (3,046) | (44)% | 25,450 | 18,645 | 6,805 | 36% | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Total cannabis revenue |
28,271 | 15,531 | 12,740 | 82% | 107,147 | 43,130 | 64,017 | 148% | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Hemp |
18,665 | — | 18,665 | N/A | 59,832 | — | 59,832 | N/A | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Total revenue |
$ | 46,936 | $ | 15,531 | $ | 31,405 | 202% | $ | 166,979 | $ | 43,130 | $ | 123,849 | 287% | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| Excise tax included in revenue |
$ | 4,429 | $ | 1,203 | $ | 3,226 | 268% | $ | 13,136 | $ | 1,200 | $ | 11,936 | N/A | ||||||||||||||||||
N/A: Not a meaningful percentage.
| PRESS RELEASE |
March 2, 2020 |
| ● | Total cannabis kilogram equivalents sold increased over 446% to 35,380 kilograms from 6,478 kilograms in the prior year. |
| ● | Average cannabis net selling price per gram decreased to $3.01 (C$3.90) compared to $6.63 (C$8.63) in the prior year. |
| ● | Net loss for the year was $321.2 million, or $3.20 per share, compared to $67.7 million, or $0.82 per share, for 2018. In 2019, the Company recorded non-cash charges of $112.1 million related to impairment of the Authentic Brands Group LLC (“ABG”) agreement as well as $68.6 million in inventory reserves. Adjusted EBITDA was a loss of $89.8 million compared to a loss of $28.3 million the prior year. |
Fourth Quarter 2019 Financial Highlights
| ● | Revenue increased 202.2% to $46.9 million (C$61.0 million), compared to the fourth quarter of last year, driven by the Canadian adult-use market, the Manitoba Harvest acquisition, and growth in international medical markets. The Company recorded reserves of $4.2 million related to discounts and returns. |
| Three months ended | ||||||||||||||||
| March 31, | June 30, | September 30, | December 31, | |||||||||||||
| Cannabis |
||||||||||||||||
| Adult-use |
$ | 7,881 | $ | 15,041 | $ | 15,834 | $ | 17,007 | ||||||||
| Canada - medical |
2,997 | 2,328 | 3,899 | 3,332 | ||||||||||||
| International - medical |
1,812 | 1,850 | 5,708 | 4,008 | ||||||||||||
| Bulk |
4,766 | 6,750 | 10,010 | 3,924 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cannabis revenue |
17,456 | 25,969 | 35,451 | 28,271 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Hemp |
5,582 | 19,935 | 15,650 | 18,665 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenue |
$ | 23,038 | $ | 45,904 | $ | 51,101 | $ | 46,936 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Excise tax included in revenue |
$ | 1,914 | $ | 3,862 | $ | 2,931 | $ | 4,429 | ||||||||
| ● | Total cannabis kilogram equivalents sold increased over seven-fold to 15,039 kilograms from 2,053 kilograms in the prior year period. |
| ● | Average cannabis net selling price per gram decreased to $1.87 (C$2.43) compared to $7.52 (C$10.05) in the prior year period. The average net selling price excluding excise taxes for adult-use was $3.19 (C$4.16) per gram for the fourth quarter of 2019. The decrease was due to a shift in product and channel mix. |
| ● | Gross margin, excluding non-cash return and inventory reserves, decreased sequentially to 29% from 31% in the prior quarter and increased compared to the fourth quarter of 2018 gross margin of 20%. Including non-cash charges, gross margin in the fourth quarter of 2019 was negative 120%. |
| ● | Net loss for the quarter was $219.1 million or $2.14 per share compared to a loss of $31.0 million or $0.33 per share for the prior year period. Adjusted EBITDA was a loss of $35.3 million compared to a loss of $13.3 million in the prior year period. The increased net loss |
| PRESS RELEASE |
March 2, 2020 |
| and Adjusted EBITDA declines were primarily due to increases in operating expenses related to growth initiatives, expansion of international teams, and the addition of Manitoba Harvest and Natura Naturals businesses. |
Senior Credit Facility
The Company closed a $60 million senior credit facility on February 28, 2020 that bears interest at prime plus 8% and has a two year term. The Company ended 2019 with $97 million in cash.
2019 Business Highlights
| ● | Canadian adult-use brand portfolio expansion: |
| o | High Park™, a subsidiary of Tilray, launched the second phase of its adult-use product portfolio including vape, edible and beverage products, across Canada where regulations allow. New brand and product additions include: |
| ◾ | Canaca – pure cannabis oil, all-in-one vape pens and cartridges; |
| ◾ | Marley Natural – pure cannabis oil vape cartridges; |
| ◾ | Chowie Wowie – cannabis-infused chocolates and gummies in THC and CBD varieties; |
| ◾ | Everie – non-alcoholic, CBD-infused ready-to-brew teas and sparkling beverages with all natural flavors. Everie is the debut brand for Fluent, Tilray’s joint venture with AB InBev, facilitated through High Park and Labatt Breweries of Canada. |
| ● | Addition of Hemp products business: |
| o | Tilray completed its acquisition of Manitoba Harvest. The Company now has hemp products available in over 17,000 retail doors and 20 countries around the world. |
| ● | Key international market developments: |
| o | Tilray Portugal received two Good Manufacturing Practice (GMP) certifications in accordance with European Union standards, for its manufacturing facility in Cantanhede, Portugal. These certifications permit the Company to manufacture and export GMP-certified bulk and finished medical cannabis products, including dried flower and oils, from Portugal to Germany and other European and international markets with legal medical cannabis regulations. Tilray remains the only licensed producer to be GMP certified in two countries, Canada and Portugal. |
| o | Successfully resupplied a bulk amount of medical cannabis in the U.K. and exported medical cannabis to Ireland. |
| o | Successfully exported medical cannabis to Germany and Israel from Portugal, and to Switzerland from Germany. In total, Tilray’s medical cannabis products have been made available in 15 countries on 5 continents across the world. |
| ● | Executive leadership team expansion: |
| PRESS RELEASE |
March 2, 2020 |
| o | Jon Levin, formerly of Revlon, joined the Company as Chief Operating Officer. |
| o | Michael Kruteck, formerly of Molson Coors and Pharmaca, joined the Company as Chief Financial Officer. Mark Castaneda, the Company’s Chief Financial Officer, will transition to a strategic business development role after the 10-K has been filed for the fiscal year ended December 31, 2019.1 |
| o | Katy Dickson, formerly of Mattel and General Mills, joined the Company as President of Manitoba Harvest. |
| ● | Clinical research developments: |
| o | Imported medical cannabis into the United States from Canada for a new clinical trial evaluating the efficacy of medical cannabis as a treatment for taxane-induced peripheral neuropathy (TIPN) secondary to treatment with paclitaxel or docetaxel. TIPN affects more than 67% of women undergoing breast cancer treatment. |
| o | Announced support for additional global clinical trials; studying the efficacy of medical cannabis as treatment in reducing severe behavioral problems in children with intellectual disabilities; and another trial examining the safety, tolerability and effectiveness of medical cannabis on immune activation in people living with HIV. |
| ● | Tilray closed its merger with Privateer Holdings, Inc. in December. |
1 Announced January 14, 2020
| PRESS RELEASE |
March 2, 2020 |
Conference Call
The Company will host a conference call to discuss these results today at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-489-6528 from the U.S. and 629-228-0736 internationally. A telephone replay will be available approximately two hours after the call concludes through Monday, March 16, 2020, by dialing 855-859-2056 from the U.S., or 404-537-3406 from international locations, and entering confirmation code 8197352.
There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will be archived for 30 days.
About Tilray®
Tilray (Nasdaq: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 15 countries spanning five continents.
Forward Looking Statements
This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements regarding our growth potential, the sustainability of growth, demand for our products and the medical and adult-use cannabis markets, anticipated plans for strategic partnerships and acquisitions, and future sales of our common stock. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 2, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
| PRESS RELEASE |
March 2, 2020 |
Use of Non-U.S. GAAP Financial Measures
To supplement its financial statements, the Company provides investors with information related to Adjusted EBITDA, which is not a financial measure calculated in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Adjusted EBITDA is calculated as net income (loss) before inventory valuation adjustments; interest expenses, net; other income, net; deferred income tax (recoveries) expenses, current income tax expenses; foreign exchange gain (loss), net; depreciation and amortization expenses; stock-based compensation expenses; other stock-based compensation related expenses; loss from equity method investments; finance income from ABG; loss on disposal of property and equipment; acquisition-related (income) expense; and amortization of inventory step-up. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. The Company believes Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. Management uses Adjusted EBITDA to compare the Company’s performance to that of prior periods for trend analyses and planning purposes. Adjusted EBITDA is also presented to the Company’s Board of Directors.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Non-U.S. GAAP measures exclude significant expenses that are required by U.S. GAAP to be recorded in the Company’s financial statements and are subject to inherent limitations.
For further information:
Media, Global: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Rachel Perkins, +1-646-277-1221, rachel.perkins@icrinc.com
| PRESS RELEASE |
March 2, 2020 |
TILRAY, INC.
Consolidated Statements of Net Loss and Comprehensive Loss
(in thousands of U.S. dollars, except for share and per share data)
| Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenue (inclusive of excise duties of $4,429, $1,203, $13,136, and $1,200, respectively) |
$ | 46,936 | $ | 15,531 | $ | 166,979 | $ | 43,130 | ||||||||
| Cost of sales |
||||||||||||||||
| Product costs |
35,870 | 8,117 | 121,892 | 24,294 | ||||||||||||
| Inventory valuation adjustments |
68,073 | 4,280 | 68,583 | 4,561 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Gross (loss) profit |
(57,007 | ) | 3,134 | (23,496 | ) | 14,275 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| General and administrative expenses |
32,462 | 12,973 | 81,968 | 29,461 | ||||||||||||
| Sales and marketing expenses |
21,923 | 6,305 | 61,084 | 15,366 | ||||||||||||
| Research and development expenses |
1,667 | 1,848 | 6,558 | 4,264 | ||||||||||||
| Stock-based compensation |
9,539 | 4,111 | 31,842 | 20,988 | ||||||||||||
| Depreciation and amortization expenses |
4,150 | 566 | 11,607 | 1,598 | ||||||||||||
| Impairment of assets |
112,070 | — | 112,070 | — | ||||||||||||
| Acquisition-related (income) expenses, net |
(24,861 | ) | 239 | (31,427 | ) | 248 | ||||||||||
| Loss from equity method investments |
2,667 | — | 4,504 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Operating loss |
(216,624 | ) | (22,908 | ) | (301,702 | ) | (57,650 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Foreign exchange (gain) loss, net |
(7,097 | ) | 6,321 | (5,944 | ) | 7,234 | ||||||||||
| Interest expenses, net |
8,685 | 7,717 | 34,690 | 9,110 | ||||||||||||
| Finance income from ABG |
(207 | ) | — | (764 | ) | — | ||||||||||
| Loss on disposal of property and equipment |
2,436 | 190 | 2,436 | 190 | ||||||||||||
| Other income, net |
3,572 | (1,588 | ) | (2,501 | ) | (2,010 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Loss before income taxes |
(224,013 | ) | (35,548 | ) | (329,619 | ) | (72,174 | ) | ||||||||
| Deferred income tax recoveries |
(4,860 | ) | (4,485 | ) | (8,847 | ) | (4,485 | ) | ||||||||
| Current income tax (recoveries) expenses |
(5 | ) | (53 | ) | 397 | 34 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Net loss |
(219,148 | ) | (31,010 | ) | (321,169 | ) | (67,723 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Net loss per share - basic and diluted |
$ | (2.14 | ) | $ | (0.33 | ) | $ | (3.20 | ) | $ | (0.82 | ) | ||||
| Weighted average shares used in computation of net loss per share - basic and diluted |
102,405,646 | 93,169,688 | 100,455,677 | 83,009,656 | ||||||||||||
| Net loss |
(219,148 | ) | (31,010 | ) | (321,169 | ) | (67,723 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Foreign currency translation gain, net |
7,588 | 127 | 5,174 | 662 | ||||||||||||
| Unrealized loss on investments |
(101 | ) | (765 | ) | (21 | ) | (765 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
| Other comprehensive income (loss) |
7,487 | (638 | ) | 5,153 | (103 | ) | ||||||||||
| Comprehensive loss |
$ | (211,661 | ) | $ | (31,648 | ) | $ | (316,016 | ) | $ | (67,826 | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
In the fourth quarter of 2019, the Company adopted ASU 2016-01, ASC 842, ASC 606 and ASU 2018-07. Each interim period in 2019 has been recast to reflect the effects of this adoption.
| PRESS RELEASE |
March 2, 2020 |
TILRAY, INC.
Consolidated Balance Sheets
(in thousands of U.S. dollars, except for share and par value data)
| December 31, 2019 | December 31, 2018 | |||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 96,791 | $ | 487,255 | ||||
| Short-term investments |
— | 30,335 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $2,015 and $292, respectively |
36,202 | 16,525 | ||||||
| Inventory |
87,861 | 16,211 | ||||||
| Prepayments and other current assets |
38,173 | 3,976 | ||||||
|
|
|
|
|
|
| |||
| Total current assets |
259,027 | 554,302 | ||||||
|
|
|
|
|
|
| |||
| Property and equipment, net |
184,217 | 80,214 | ||||||
| Operating lease, right-of-use assets |
17,514 | — | ||||||
| Intangible assets, net |
228,828 | 4,486 | ||||||
| Goodwill |
163,251 | — | ||||||
| Equity method investments |
11,448 | — | ||||||
| Other investments |
24,184 | 16,911 | ||||||
| ABG finance receivable and other assets |
7,861 | 754 | ||||||
|
|
|
|
|
|
| |||
| Total assets |
$ | 896,330 | $ | 656,667 | ||||
|
|
|
|
|
|
| |||
| Liabilities |
||||||||
| Current liabilities |
||||||||
| Accounts payable |
39,125 | 10,649 | ||||||
| Accrued expenses and other current liabilities |
50,829 | 14,818 | ||||||
| Accrued obligations under finance lease |
— | 470 | ||||||
| Accrued obligations under operating lease |
2,473 | — | ||||||
|
|
|
|
|
|
| |||
| Total current liabilities |
92,427 | 25,937 | ||||||
|
|
|
|
|
|
| |||
| Accrued obligations under finance lease |
14,152 | 8,286 | ||||||
| Accrued obligations under operating lease |
15,255 | — | ||||||
| ABG finance liability |
5,566 | — | ||||||
| Deferred tax liability |
53,363 | 4,424 | ||||||
| Convertible notes, net of issuance costs |
430,210 | 420,367 | ||||||
| Other liabilities |
86 | — | ||||||
|
|
|
|
|
|
| |||
| Total liabilities |
$ | 611,059 | $ | 459,014 | ||||
|
|
|
|
|
|
| |||
| Commitments and contingent liabilities |
||||||||
| Stockholders’ equity |
||||||||
| Class 1 common stock ($0.0001 par value, 250,000,000 shares authorized; 16,666,667 shares issued and outstanding) |
2 | 2 | ||||||
| Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized; 86,114,558 and 76,504,200 shares issued and outstanding, respectively) |
9 | 8 | ||||||
| Additional paid-in capital |
705,671 | 302,057 | ||||||
| Accumulated other comprehensive income |
9,719 | 3,763 | ||||||
| Accumulated deficit |
(430,130 | ) | (108,177 | ) | ||||
|
|
|
|
|
|
| |||
| Total stockholders’ equity |
$ | 285,271 | $ | 197,653 | ||||
|
|
|
|
|
|
| |||
| Total liabilities and stockholders’ equity |
$ | 896,330 | $ | 656,667 | ||||
|
|
|
|
|
|
| |||
| PRESS RELEASE |
March 2, 2020 |
| Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||
|
|
|
| ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Adjusted EBITDA reconciliation: |
||||||||||||||||
| Net loss |
$ | (219,148 | ) | $ | (31,010 | ) | $ | (321,169 | ) | $ | (67,723 | ) | ||||
| Inventory valuation adjustments |
68,073 | 4,280 | 68,583 | 4,561 | ||||||||||||
| Depreciation and amortization expenses |
5,421 | 1,009 | 15,849 | 3,562 | ||||||||||||
| Stock-based compensation expenses |
9,539 | 4,111 | 31,842 | 20,988 | ||||||||||||
| Other stock-based compensation related expenses |
8,411 | — | 8,411 | — | ||||||||||||
| Impairment of assets |
112,070 | — | 112,070 | — | ||||||||||||
| Acquisition-related (income) expenses, net |
(24,861 | ) | 239 | (31,427 | ) | 248 | ||||||||||
| Loss from equity method investments |
2,667 | — | 4,504 | — | ||||||||||||
| Foreign exchange (gain) loss, net |
(7,097 | ) | 6,321 | (5,944 | ) | 7,234 | ||||||||||
| Interest expenses, net |
8,685 | 7,717 | 34,690 | 9,110 | ||||||||||||
| Finance income from ABG |
(207 | ) | — | (764 | ) | — | ||||||||||
| Loss on disposal of property and equipment |
2,436 | 190 | 2,436 | 190 | ||||||||||||
| Other income, net |
3,572 | (1,588 | ) | (2,501 | ) | (2,010 | ) | |||||||||
| Amortization of inventory step-up |
— | — | 2,041 | — | ||||||||||||
| Deferred income tax (recoveries) expenses |
(4,860 | ) | (4,485 | ) | (8,847 | ) | (4,485 | ) | ||||||||
| Current income tax expenses |
(5 | ) | (53 | ) | 397 | 34 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||
| Adjusted EBITDA |
$ | (35,304 | ) | $ | (13,269 | ) | $ | (89,829 | ) | $ | (28,291 | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||
| Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||
|
|
|
| ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Adjusted net loss reconciliation: |
||||||||||||||||
| Net loss |
$ | (219,148 | ) | $ | (31,010 | ) | $ | (321,169 | ) | $ | (67,723 | ) | ||||
| Inventory valuation adjustments |
68,073 | 4,280 | 68,583 | 4,561 | ||||||||||||
| Impairment of assets |
112,070 | — | 112,070 | — | ||||||||||||
| Acquisition-related (income) expenses, net |
(24,861 | ) | 239 | (31,427 | ) | — | ||||||||||
| Amortization of inventory step-up |
— | — | 2,041 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||
| Adjusted net loss |
$ | (63,866 | ) | $ | (26,491 | ) | $ | (169,902 | ) | $ | (63,162 | ) | ||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||
| Adjusted net loss per share - basic and diluted |
(0.62 | ) | (0.28 | ) | (1.69 | ) | (0.76 | ) | ||||||||
| Weighted average shares used in computation of adjusted |
||||||||||||||||
| Net loss per share - basic and diluted |
102,405,646 | 93,169,688 | 100,455,677 | 83,009,656 | ||||||||||||